SPN-817
Severe Epilepsy
Phase 2Active
Key Facts
About Supernus Pharmaceuticals
Supernus Pharmaceuticals is a publicly traded CNS-focused biopharmaceutical company with a mission to improve patient lives through innovative neurology and psychiatry treatments. The company has successfully built a commercial foundation with eight marketed products and is advancing a pipeline featuring late-stage candidates for treatment-resistant depression and severe epilepsy. Its strategy combines internal R&D powered by proprietary drug delivery platforms with strategic acquisitions, such as Sage Therapeutics, to solidify its position as a comprehensive CNS therapeutics leader.
View full company profile